· 12 min read
What is a Pharmaceutical CDMO, and How Do You Choose One?
A CDMO takes a product from formulation through to commercial supply. Learn what a pharmaceutical CDMO does, how formulation development fits in, and what to check before choosing a partner in India.
What is a pharmaceutical CDMO, and how do you choose one?
A contract development and manufacturing organisation (CDMO) can take a product from formulation through to commercial supply. This guide explains what a CDMO does, where formulation development fits, and what to check before choosing a partner in India.
Bringing a medicine to market involves more than making the tablet, capsule, solution or injection. The product has to be designed, tested, documented and manufactured in a way that a regulator will accept. Many pharmaceutical companies therefore work with a CDMO for some or all of those steps.
For a company looking for a formulation development partner, the useful question is not only who can manufacture. It is who can design the product, prove its quality and hand it over cleanly to manufacturing.
What does a pharmaceutical CDMO do?
A CDMO, or contract development and manufacturing organisation, develops and/or manufactures medicines on behalf of other pharmaceutical companies. The client may be a generics company, an originator, or a developer with a new product and no in-house facility.
In short: a CDMO works on a product for another company. Its scope can be a single service, such as analytical testing, or a full programme from formulation to commercial supply.
Typical services include formulation development, analytical development, technology transfer, regulatory affairs, bioequivalence support, commercial supply and audit support. Not every CDMO offers all of them, so it helps to map your programme to the services you actually need.
CDMO vs CRO: what is the difference?
The terms are often confused. A CRO (contract research organisation) usually runs studies, such as clinical trials or bioequivalence work. A CDMO focuses on developing and making the product itself. Many programmes need both.
| Factor | CDMO | CRO |
|---|---|---|
| Main focus | Developing and making the product | Running studies and generating data |
| Typical services | Formulation, analytical development, technology transfer, supply | Clinical trials, bioequivalence studies, data management |
| Output | A developed, documented and manufactured product | Study results and reports |
Why formulation development is central
Formulation development decides how the active ingredient, excipients, process and dosage form work together. The aim is a product that performs as intended and can be manufactured and controlled consistently.
Formulation work differs by dosage form. Oral solids, oral liquids, semi-solids and topicals each raise different questions about release, stability and manufacturing. Sterile injectables and ophthalmic products add further requirements. A partner with experience across several of these forms can usually plan more realistically for a new product.
The development journey, step by step
A typical programme moves through connected stages. Each one depends on the decisions made in the previous stage, which is why handovers between teams matter so much.
Molecule and preformulation
Understand the active ingredient before designing the product, including its solubility and dissolution behaviour.
Formulation development
Design the dosage form against a defined target product profile, selecting excipients and process conditions.
Analytical development
Develop and validate methods so the data generated during development can support the dossier.
Technology transfer
Move the process to a receiving site in a documented way, with scale-up assessment and exhibit batches.
Regulatory work runs alongside these stages rather than after them. Stability data, method validation and manufacturing controls all feed into the dossier, so planning for them early avoids rework later.
Quality by design starts before the first batch
Quality is easier to build in than to test in. A structured approach defines the quality attributes the product must meet, then identifies the formulation and process variables that affect them.
- QTPP and CQAs: define the target product profile and the critical quality attributes that follow from it.
- QbD and DoE: use Quality by Design principles and Design of Experiments to understand how variables interact.
- Validated methods: make sure the analytical methods behind every decision are validated before anyone relies on their data.
- ICH stability: generate stability data that supports the shelf life and the regulatory filing.
- Documentation: keep records that a regulator or auditor can follow from start to finish.
How to choose a formulation development partner in India
Comparing CDMOs on manufacturing capacity alone can miss the most important risks. These checks give a more useful picture:
Does the partner have formulation experience in your dosage form and therapeutic area?
Can its analytical team characterise the product and develop methods that meet your target market?
Is there a documented technology-transfer and scale-up process?
Does it have experience with regulators in your intended markets, such as the US, Europe or other regulated markets?
Are the quality management system and certifications current and verifiable?
Can the same team support the project from early development through to commercial supply?
Ask for evidence rather than claims. Practical examples include a list of dosage forms developed, the markets a partner has filed in, and how it handles out-of-specification and out-of-trend results.
Frequently asked questions
What is a pharmaceutical CDMO?
A CDMO is a company that develops and/or manufactures medicines for other pharmaceutical companies. Its scope can range from formulation development and analytical work to regulatory support and commercial supply.
What is the difference between a CDMO and a CRO?
A CRO mainly runs studies such as clinical trials or bioequivalence work. A CDMO focuses on developing and making the product. Many programmes use both.
When should a company bring in a formulation development partner?
Early is usually better. Involving a partner during preformulation and formulation design helps avoid rework when analytical, stability and regulatory work begins.
Planning a formulation development programme?
Tell us the molecule, the dosage form and the market you are filing in. A programme lead will read it and reply with what we would do next.